Beam Therapeutics Inc. Payments of Stock Issuance Costs
Beam Therapeutics Inc. (BEAM) reported Payments of Stock Issuance Costs of $631.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2025-02-25
- Beam Therapeutics Inc. payments of stock issuance costs for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Beam Therapeutics Inc. payments of stock issuance costs for the quarter ending 2023-09-30 was $384.00K, a 1436.00% increase year-over-year.
- Beam Therapeutics Inc. payments of stock issuance costs for the quarter ending 2023-06-30 was $185.00K, a 79.61% increase year-over-year.
- Beam Therapeutics Inc. payments of stock issuance costs for the quarter ending 2023-03-31 was $62.00K, a 933.33% increase year-over-year.
- Beam Therapeutics Inc. payments of stock issuance costs for fiscal 2023 was $631.00K, a 235.64% increase from fiscal 2022.
- Beam Therapeutics Inc. payments of stock issuance costs for fiscal 2022 was $188.00K, a 97.87% decline from fiscal 2021.
- Beam Therapeutics Inc. payments of stock issuance costs for fiscal 2021 was $8.82M, a 328.17% increase from fiscal 2020.
- Beam Therapeutics Inc. payments of stock issuance costs for fiscal 2020 was $2.06M, a 18.33% decline from fiscal 2019.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $384.00K derived: sum of 2 quarters · filed 2025-02-25 | $569.00K derived: sum of 3 quarters · filed 2025-02-25 | $631.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | $384.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $569.00K derived: sum of 2 quarters · filed 2024-11-05 | $631.00K 10-Q · filed 2024-11-05 | $685.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $185.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $247.00K 10-Q · filed 2024-08-06 | $301.00K derived: sum of 3 quarters · filed 2025-02-25 | $326.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $62.00K 10-Q · filed 2024-05-07 | $116.00K derived: sum of 2 quarters · filed 2025-02-25 | $141.00K derived: sum of 3 quarters · filed 2025-02-25 | $244.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $79.00K derived: sum of 2 quarters · filed 2025-02-25 | $182.00K derived: sum of 3 quarters · filed 2025-02-25 | $188.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $128.00K derived: sum of 2 quarters · filed 2023-11-08 | $134.00K 10-Q · filed 2023-11-08 | $262.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $109.00K 10-Q · filed 2023-08-08 | $237.00K derived: sum of 3 quarters · filed 2024-02-27 | $446.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $6.00K 10-Q · filed 2023-05-10 | $134.00K derived: sum of 2 quarters · filed 2024-02-27 | $343.00K derived: sum of 3 quarters · filed 2024-02-27 | $867.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $337.00K derived: sum of 2 quarters · filed 2024-02-27 | $861.00K derived: sum of 3 quarters · filed 2024-02-27 | $8.82M 10-K · filed 2024-02-27 |
| 2021-09-30 | $209.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $733.00K derived: sum of 2 quarters · filed 2022-11-07 | $8.69M 10-Q · filed 2022-11-07 | $9.03M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $524.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $8.48M 10-Q · filed 2022-08-09 | $8.82M derived: sum of 3 quarters · filed 2023-02-28 | $8.87M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $7.96M 10-Q · filed 2022-05-09 | $8.30M derived: sum of 2 quarters · filed 2023-02-28 | $8.35M derived: sum of 3 quarters · filed 2023-02-28 | $9.06M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $394.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.10M derived: sum of 3 quarters · filed 2023-02-28 | $2.06M 10-K · filed 2023-02-28 |
| 2020-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $759.00K derived: sum of 2 quarters · filed 2021-11-08 | $1.72M 10-Q · filed 2021-11-08 | $3.15M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $707.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $1.67M 10-Q · filed 2021-08-10 | $3.10M derived: sum of 3 quarters · filed 2022-02-28 | $4.12M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $958.00K 10-Q · filed 2020-05-12 | $2.39M derived: sum of 2 quarters · filed 2022-02-28 | $3.41M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.45M derived: sum of 2 quarters · filed 2022-02-28 | $2.52M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.09M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $68.00K 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |